EU/3/18/2100

About

On 19 November 2018, orphan designation (EU/3/18/2100) was granted by the European Commission to Quality Regulatory Clinical Ireland Limited, Ireland, for propagermanium for the treatment of focal segmental glomerulosclerosis.

The sponsorship was transferred to Raremoon Consulting Esp S.L., Spain in June 2020.

Key facts

Active substance
propagermanium
Disease / condition
Treatment of focal segmental glomerulosclerosis
Date of first decision
19/11/2018
Outcome
Positive
EU designation number
EU/3/18/2100

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Raremoon Consulting Esp S.L.
Ronda De Sant Pere 33 Ppal 3 Y 4
08010 Barcelona
Spain
Tel. +34 93 488 0972
E-mail: sabrina@raremoonconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating